Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia

Area of Science:

• Nephrology
• Cardiology
• Clinical Pharmacology

Background:

• Hyperkalemia is a common electrolyte disturbance linked to adverse outcomes, including mortality and arrhythmias.
• Patients with chronic kidney disease, diabetes, or heart failure are particularly susceptible to hyperkalemia.
• Existing potassium binders have limitations such as slow onset, poor selectivity, drug interactions, and gastrointestinal intolerance.

Purpose of the Study:

• To introduce Sodium Zirconium Cyclosilicate (SZC) as a novel therapeutic agent for managing chronic hyperkalemia.
• To highlight the unique properties and advantages of SZC compared to current potassium-binding therapies.
• To evaluate the efficacy, safety, and tolerability of SZC in hyperkalemia treatment.

Main Methods:

• SZC is a nonabsorbable, inorganic crystal that selectively binds potassium and ammonium ions.
• It exchanges potassium and ammonium for Na+ and H+ throughout the gastrointestinal tract.
• Clinical studies assessed its ability to rapidly correct and maintain normal serum potassium levels.

Main Results:

• SZC rapidly corrects serum potassium levels within 2 days.
• It maintains normokalemia for up to 1 year with good tolerability.
• Efficacy is maintained regardless of renin-angiotensin-aldosterone system inhibitor (RAASI) use.
• Common adverse events include gastrointestinal issues and dose-dependent edema; drug interaction potential is low.

Conclusions:

• Sodium Zirconium Cyclosilicate (SZC) is a new, effective, and well-tolerated option for treating chronic hyperkalemia.
• Its selective binding and rapid onset address limitations of older potassium binders.
• SZC provides a valuable therapeutic alternative, especially for patients on RAASIs.